linjc16/ctgov huggingface dataset:
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

Study Overview
=================
Brief Summary
-----------------
Susceptibility testing is commonly employed in patients with bacterial infections in order to guide rational use of antibiotics; however, the use of antifungal susceptibility testing is limited due to lack of availability, costs, and delays in receiving results. The goals of antifungal susceptibility testing should mirror those of antibacterial susceptibility testing: to predict clinical response or failure. Additionally, susceptibility reports should be used as a guide for physicians when transitioning patients from parenteral to oral antifungal agents. Currently, it is unknown whether antifungal susceptibility testing impacts treatment decisions in hospitals that routinely perform Candida susceptibility testing. The purpose of this study is to evaluate the changes in antifungal treatment based on in vitro susceptibility reports and how these decisions affect mortality, recurrence of infection, and length of hospital stay in candidemia patients.

Official Title
-----------------
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

Conditions
-----------------
Blood Stream Infections, Candida

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients with bloodstream infections due to Candida species Exclusion Criteria: Patients will be excluded from this study if their medical charts contain incomplete outcome or susceptibility data. Patients treated empirically or definitively with amphotericin-based products will also be excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hospitalized patients with candidemia<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess empiric choice of antifungal therapy in hospitalized patients with candidemia. |  | Assessments made for 30-days after postivie blood culture | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
susceptibility testing
Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ

Study Overview
=================
Brief Summary
-----------------
This investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the investigative full face mask amongst OSA participants.

Detailed Description
-----------------
A total number of up to 15 OSA participants who currently use full face masks will be recruited for the trial. Participants will be on the trial for three weeks, using the prototypes at home for two weeks. PAP baseline data on the participant's prescribed treatment pressure with their usual mask and will be collected for one week prior to mask fitting with the full face trial mask.

Official Title
-----------------
Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Device: F&P Jupiter Full Face Mask


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18+ years of age Diagnosed with OSA by a practicing physician Prescribed PAP therapy (Bi-Level or Continuous Positive Airway Pressure (CPAP) or Automatic Positive Airway Pressure (APAP)) Existing full face users Exclusion Criteria: Inability to give informed consent Patients who are in a coma or decreased level of consciousness Anatomical or physiological conditions making PAP therapy inappropriate (e.g unconsolidated facial fracture) Commercial Drivers who are investigated by New Zealand Transport Agency (NZTA) Current diagnosis of CO2 retention Pregnant or think they may be pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Full Face Mask<br>F&P Jupiter Full Face Mask with Headgear | Device: F&P Jupiter Full Face Mask<br>* Investigative F&P Jupiter full face mask to be used for OSA therapy<br>* Other names: Jupiter Mask;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with average system leak >60L/min | Average system leak will be recorded through downloading of the data from the PAP device in L/min. | Two weeks in-home use | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insights into mask fitting and removal. | Observations of the action of fitting the mask and removing the mask will be noted. | Two weeks use | 
| Number of participants that found the mask comfortable. | Subjective feedback on comfort will be measured through questionnaires. | Two weeks in-home use |
ASTERIX: Low Dose ASA and Nexium

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.

Official Title
-----------------
A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.

Conditions
-----------------
Gastroesophageal Reflux

Intervention / Treatment
-----------------
* Drug: Esomeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A clinical diagnosis of a condition (cardiovascular and/or cerebrovascular protection or other reasons) that requires daily intake of low-dose ASA, 75-325 mg, and is expected to continue for the duration of the study (daily is defined as at least 5 days per week). Age >= 60 years. No gastric and/or duodenal ulcer at the baseline endoscopy. H. pylori negative by serology test at screening. Exclusion Criteria: Upper GI symptoms Erosive oesophagitis Malignancy

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Esomeprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary variable is presence of gastric and/or duodenal ulcers at endoscopy over a 26-week period in patients taking low-dose ASA. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LA classification for the oesophagus at endoscopy. Upper GI symptoms assessed by the investigator at each study visit. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of gastroduodenal lesions, erosive oesophagitis, upper GI symptoms
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia

Study Overview
=================
Brief Summary
-----------------
Investigation of the clinical condition and safety in patients with cervical dystonia

Conditions
-----------------
Cervical Dystonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients with cervical dystonia Exclusion criteria: The patients who participated in this surveillance in the past
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| E2014<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall assessments of the improvement in the seriousness of seizures | Improvement is based on the 5 following elements: 1) Eminent improvement 2) Improvement 3) Improvement a little invariability 5) Exacerbation 6) It is not possible to judge | Up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Torticollis, rimabotulinumtoxinB
Neural Mechanism of Cortisol Awakening Response Suppression Effect on Human High-order and Social Cognitions

Study Overview
=================
Brief Summary
-----------------
CAR is short for cortisol awakening response. The neural mechanism of CAR effect on high-order cognition and social cognition is less known...

Official Title
-----------------
Neural Mechanism of Cortisol Awakening Response Suppression Effect on Human High-order and Social Cognitions

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Dexamethasone
* Drug: Vitamin C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy college students. Exclusion Criteria: Current or history of psychiatric or neurological illness. Current use of any medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 26 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group1<br>take Dexamethasone at 22:00 on the first day, 0.5mg | Drug: Dexamethasone<br> <br> |
| Placebo Comparator: group2<br>take Vitamin C at 22:00 on the first day, 0.5mg | Drug: Vitamin C<br> <br> |
| Other: group3<br>take Dexamethasone at 15:00 on the second day, 0.5mg | Drug: Dexamethasone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cortisol Awakening Response Level(nmol/L) after Taking Dexamethasone | The dosage of Dexamethasone is 0.5mg. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cortisol Awakening Response suppression, Dexamethasone Suppression Test, high-order cognition, social cognition
MR-Guided Laser Ablation of Prostate Bed Recurrences

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if MR-guided laser ablation can effectively treat prostate tumor recurrences.

Official Title
-----------------
Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Prostate Bed Recurrences

Conditions
-----------------
Prostate Tumors

Intervention / Treatment
-----------------
* Procedure: MR-Guided Laser Ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with biopsy proven soft tissue tumor recurrences of prostate fossa referred to Urology and/or Interventional Radiology for treatment. Surgery is not a desirable alternative therapy at the time of enrollment Radiation therapy has failed or not indicated or can be safely postponed Tumor size ≤ 5 cm at its largest diameter Tumor does not encompass the rectal wall or external urethral sphincter Performance status is ECOG 2 or better in adults Patient is able to undergo MRI Exclusion Criteria: Patients with pacemaker or defibrillator

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MR-Guided Laser Ablation<br> | Procedure: MR-Guided Laser Ablation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of target lesion(s) dimensions at 3-6 month imaging follow-up |  | 3-6 months |
Assessment of an Electronic Voting System Within the Tutorial Setting. A Randomised Controlled Trial

Study Overview
=================
Brief Summary
-----------------
A study of an electronic voting system as a learning aid during tutorials

Detailed Description
-----------------
A study of an electronic voting system as a learning aid during tutorials. This study was undertaken with clinical students over a one year period of observation

Official Title
-----------------
Assessment of an Electronic Voting System Within the Tutorial Setting. A Randomised Controlled Trial

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Effect of an electronic voting system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All fourth year students
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Effect of an electronic voting system|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Electronic voting system
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of CTO0101

Official Title
-----------------
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: CTO0101
* Other: Placebo (vehicle)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female volunteers Written informed consent to participate in the trial Exclusion Criteria: Those who have a history of ophthalmic diseases and surgery within 5 years Smokers with an average daily smoking amount exceeding 10 cigarettes

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CTO0101<br> | Drug: CTO0101<br>* 1 drop/ once or three times a day/ for 17 days divided into stage2<br>|
| Placebo Comparator: Placebo (Vehicle)<br> | Other: Placebo (vehicle)<br>* 1 drop/ once or three times a day/ for 17 days divided into stage2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax,ss |  | Day8 of stage 2 | 
| Tmax,ss |  | Day8 of stage 2 | 
| t1/2,ss |  | Day8 of stage 2 | 
| AUCτ,ss |  | Day8 of stage 2 | 
| RAAUCτ |  | Day8 of stage 2 |
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).

Official Title
-----------------
Diagnostic Accuracy of Delayed MRI Contrast Enhancement Characteristics and Radiation Necrosis Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Conditions
-----------------
Brain Metastases

Intervention / Treatment
-----------------
* Other: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, age ≥18 Metastatic malignancy with at least 1 brain metastasis previously treated with SRS Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma. Radiographic progression on post-SRS imaging at previously treated SRS site(s) Must be a candidate for brain surgery as determined by treating neurosurgeon and/or anesthesia team Patients must sign study-specific informed consent prior to study entry Exclusion Criteria: Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy) Small cell lung cancer (SCLC) or lymphoma histology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MRI<br> | Other: MRI<br>* Subjects undergo one additional delayed MRI sequence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of positive MRI sequences along with positive tumor biopsies | true tumor will be detected by delayed MRI as determined by biopsy | baseline | 
| number of negative MRI sequences along with negative tumor biopsies | absence of tumor will be detected by delayed MRI as determined by biopsy | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stereotactic radiosurgery (SRS), Laser Interstitial Thermal Therapy (LITT), Magnetic resonance image (MRI)
Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant

Study Overview
=================
Brief Summary
-----------------
Human herpesvirus-6 (HHV-6) and -7 (HHV-7) infections are common after transplantation. Such infections may predispose transplant patients to other infections, contribute to a recurrence of hepatitis C virus, and affect rejection and function of the transplanted liver. Given the significant clinical impact of these viruses, routine laboratory monitoring may be beneficial by identifying patients who have persistent or high levels of infection. In these patients, immunosuppressive medications could be adjusted, or antiviral medications administered. There are currently no randomized trials that address this important question. This prospective, randomized trial will analyze whether routine laboratory monitoring for HHV-6 and -7 is clinically useful, and whether it would improve overall outcomes in transplant recipients.

Official Title
-----------------
The Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant: A Randomized Trial

Conditions
-----------------
Transplant

Intervention / Treatment
-----------------
* Procedure: Monitoring - blood samples drawn to test for HHV-6 and HHV-7


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients who fulfill the following criteria are eligible for inclusion: Recipients of a liver transplant Able to give written informed consent Are willing and able to comply with the protocol Age >= 18 years Exclusion Criteria: The following patients are not eligible for inclusion in the study: Patients unwilling or unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Monitoring - blood samples drawn to test for HHV-6 and HHV-7|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse clinic events due to direct or indirect effects. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver transplant, HHV-6, HHV-7, Human Herpesvirus-6, Human Herpesvirus-7